• Discover. Engage. Learn on demand.

    Welcome to OncoConnect, where you can access the latest information within Takeda Oncology, online educational resources and sign-up for online and live events.

     

    people in a lab.

  • Register to unlock essential resources

    Sign up today to make the most of OncoConnect, including connecting with your peers, listening to experts in Oncology and unlocking valuable resources for you and your patients.

    REGISTER NOW

    doctor and patient.

  • Get in touch

    Reach out to one of our Key Account Managers, or Medical Science Liaison team, to discuss Takeda medicines or scientific information.

    BOOK A MEETING

    people looking at screen.
New on OncoConnect
Wilson_Osborne_Exploring Case Studies
Prescribing information Adcetris
Expert-led podcast: Exploring sALCL case studies and the treatment landscape

Listen to Dr Matthew Wilson, Consultant Haematologist at the Beatson West of Scotland Cancer Centre, and Dr Wendy Osborne, Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust, discuss diverse clinical presentations of sALCL and their personal management strategies by exploring two real-world patient case studies. 

Whittaker_Osborne_Navigating Treatment
Prescribing information Adcetris
Expert-led podcast: Navigating the assessment and treatment of CTCL

Listen to clinical experts explore the heterogeneous nature of CTCL, defining the subtypes MF, pcALCL and SS. Professor Whittaker, Consultant Dermatologist at Guy’s and St. Thomas’ NHS Foundation Trust, and   

Scarisbrick_Osborne_Expert Approaches
Prescribing information Adcetris
Expert-led podcast: Multidisciplinary management of CTCL

Listen to Professor Julia Scarisbrick, Consultant Dermatologist at University Hospital Birmingham NHS Foundation Trust, and Dr Wendy Osborne, Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust, discuss the multidisciplinary management of adult patients with CTCL. They explore the role of haematologists, dermatologists, oncologists and clinical nurse specialists in managing these patients. 

Prescribing information Adcetris
ADCETRIS® (brentuximab vedotin) in combination with CHP as a treatment option for adult patients with previously untreated sALCL

This digital resource summarises the key efficacy and safety data from the ECHELON-2 study,3 which investigated ADCETRIS + CHP vs CHOP in adult patients with previously untreated sALCL.

Prescribing information Ninlaro
Real-world evidence: Treating patients with RRMM with prior lenalidomide exposure

The INSURE study is a pooled, global analysis of three observational studies (INSIGHT MM, UVEA-IXA and REMIX).1 Results from this study demonstrated minimal impact of prior lenalidomide exposure on the effectiveness of NINLARO® (ixazomib) with lenalidomide and dexamethasone (NRd) in lenalidomide-non-refractory adult patients with RRMM treated in routine clinical practice.1 It was concluded that prior lenalidomide exposure (but not refractoriness) should not preclude the use of NRd in later lines of treatment in patients with RRMM, and no new safety concerns were reported for NRd.1 

Jackson_Lenalidomide Rechallenge
Prescribing information Ninlaro
How can we determine whether lenalidomide rechallenge is an option for patients with RRMM?

Lenalidomide has become an integral part of first-line treatment in patients with multiple myeloma.1 As patients progress to later lines, options can become limited, and the choice of treatment offered in patients who relapse should be carefully evaluated.2 Defining and understanding the lenalidomide status of patients with multiple myeloma can help guide the next line of treatment and which patients can be rechallenged appropriately with lenalidomide post relapse.

Initiating Patient_Clark
Prescribing information Alunbrig
ALUNBRIG® (brigatinib) Expert Opinion Video Series: Initiating patients on ALUNBRIG

Listen to Dr Brian Clark share his experience of initiating ALUNBRIG in patients with ALK+ aNSCLC to gain insight that can be translated into your own clinical practice. 

Dr Clark discusses the recommended ALUNBRIG dosing regimen, and highlights the availability of the starter pack and provision of the patient alert card for your patients with ALK+ aNSCLC.

 

QOL_Summers
Prescribing information Alunbrig
ALUNBRIG® (brigatinib) Expert Opinion Video Series: Impact of brain metastases on patients with ALK+ aNSCLC and ALUNBRIG quality of life (QOL) data from the ALTA-1L study

Listen to Dr Yvonne Summers discuss the current unmet needs of patients with ALK+ aNSCLC, including the negative impact of brain metastases on the daily lives of these patients. 

Dr Summers provides an overview of the ALUNBRIG health-related QOL data from the ALTA-1L study in patients with ALK+ aNSCLC and how these results compare with her real-world experience in clinical practice. 

Managing Toxicities_Ghosh
Prescribing information Alunbrig
ALUNBRIG® (brigatinib) Expert Opinion Video Series: Managing toxicities and side effects associated with ALUNBRIG

Listen to Dr Sharmistha Ghosh who shares her experience on the management of patients with ALK+ aNSCLC during treatment with ALUNBRIG, including the specific monitoring required.